# Oblimersen Sodium & Combination Chemotherapy in Treating Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma

> **NCT00736450** · EARLY_PHASE1 · TERMINATED · sponsor: **University of Nebraska** · enrollment: 37 (actual)

## Conditions studied

- Contiguous Stage II Adult Diffuse Large Cell Lymphoma
- Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma
- Stage I Adult Diffuse Large Cell Lymphoma
- Stage III Adult Diffuse Large Cell Lymphoma
- Stage IV Adult Diffuse Large Cell Lymphoma

## Interventions

- **BIOLOGICAL:** oblimersen sodium
- **BIOLOGICAL:** rituximab
- **DRUG:** cyclophosphamide
- **DRUG:** doxorubicin hydrochloride
- **DRUG:** vincristine sulfate
- **DRUG:** prednisone
- **PROCEDURE:** biopsy
- **GENETIC:** microarray analysis
- **OTHER:** immunohistochemistry staining method
- **GENETIC:** gene expression analysis
- **GENETIC:** cytogenetic analysis

## Key facts

- **NCT ID:** NCT00736450
- **Lead sponsor:** University of Nebraska
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-07-23
- **Primary completion:** 2012-10-09
- **Final completion:** 2012-10-09
- **Target enrollment:** 37 (ACTUAL)
- **Why stopped:** Manufacturer is no longer making the drug.
- **Last updated:** 2023-10-24

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00736450

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00736450, "Oblimersen Sodium & Combination Chemotherapy in Treating Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00736450. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*